Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

Esther Sanfeliu; Anabel Martínez-Romero; Mercedes Marín‐Aguilera; Sandra Cobo; Blanca González‐Farré; Eva Hernández‐Illán; Pedro Jares; Joan Anton Puig‐Butille; Montserrat Muñoz-Mateu; Raquel Gómez-Bravo; Marta Tapia; Cristina Tebar; Cristina Saura; Santiago Escrivá-de-Romaní; Jesús Soberino; Javier Cortés; Serafin M. Morales; Kepa Amillano; Laia Paré; Patricia Villagrasa; Wesley Buckingham; Francisco Pardo; Joel S. Parker; Fara Brasó‐Maristany; Eva Ciruelos; Rodrigo Sánchez-Bayona; Olga Martínez‐Sáez; Juan Miguel Cejalvo; Aleix Prat

doi:10.1158/1078-0432.31249007

Figure 1 from Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

2026 Open access

Read full text

Authors: Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín‐Aguilera, Sandra Cobo, Blanca González‐Farré, Eva Hernández‐Illán, Pedro Jares, Joan Anton Puig‐Butille, Montserrat Muñoz-Mateu, Raquel Gómez-Bravo, Marta Tapia, Cristina Tebar

+17 more

Cristina Saura, Santiago Escrivá-de-Romaní, Jesús Soberino, Javier Cortés, Serafin M. Morales, Kepa Amillano, Laia Paré, Patricia Villagrasa, Wesley Buckingham, Francisco Pardo, Joel S. Parker, Fara Brasó‐Maristany, Eva Ciruelos, Rodrigo Sánchez-Bayona, Olga Martínez‐Sáez, Juan Miguel Cejalvo, Aleix Prat

DOI: 10.1158/1078-0432.31249007

Cited by: 0

Abstract

Overview of patient and tumor characteristics. Patient distribution across the top 10 hospitals by enrollment (A), tumor grade (B), HR status (C), HER2 IHC status (D), Ki67 expression (E), stromal TIL percentage (F), TIL grouped as

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Gastric Cancer Management and Outcomes

Publication details

Publication date: 4 February 2026